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Objectives: The success of vaccination strategies depends in part on population perceptions of benefits
and risks of vaccines and related confidence in vaccination. Better knowledge of public concerns about
vaccines and what is driving them is needed to inform vaccination strategies and communications.
This literature reviewer examined studies on vaccine and vaccination risk perceptions and concerns
across European populations.
Methods: A systematic literature review was conducted to identify studies published between 2004 and
2014 in Europe. A descriptive analysis was performed.
Findings: A total of 145 articles were selected, most of which were conducted in the UK, the Netherlands
and France and studied seasonal influenza, HPV and pandemic influenza vaccination. Across all countries
and vaccines, the primary area of concern was vaccine safety, followed by perceptions of low likelihood of
contracting vaccine-preventable diseases (VPDs), perceived low severity of VPDs, beliefs that vaccines do
not work, and overall lack of information. Concerns were found to be vaccine-, country- and population-
specific.
Conclusion: In addition to identifying concerns about vaccination in Europe, this study confirmed the
notion that individuals have many safety concerns about vaccination and often believe that the risks
of vaccination outweigh their benefits. More research needs to be conducted to explore the impact of dif-
ferent types of communication strategies, which would frame the benefits of vaccination as well as risks
of not vaccinating. Strategies to better inform public perceptions of vaccines should include the provision
of unbiased, comprehensive information tailored to population information needs, and delivered using
multiple and new communication technologies such as social media.
 2017 Published by Elsevier Ltd.
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1. Introduction
Ever since the development of the first vaccines, individuals
have raised concerns about the risks of vaccination [1]. Studies
have tried to explain refusals or delays in vaccination as a conse-
quence of imbalance between perception of the risks and benefits
of vaccination: individuals weighing risks of vaccination higher
than its benefits will tend to refuse or delay some or all vaccines
[2–4].
As risks and benefits lack a common unit of assessment, they
cannot easily be compared [5]. Furthermore, individuals have been
shown to assess vaccination risks compared to other risks (i.e. dis-
eases) differently than experts. Rather than mathematically weigh-
ing risks and benefits at the population level, individuals often rely
on information consisting of individual stories and narratives
which influence fear and uncertainties [6]. Parents will, for
instance, think about the risks of vaccinating their children against
risks of suffering from vaccine preventable diseases (VPDs) and
will make a decision in favour of what they perceive as the ‘‘least
risky option”.
Risk perception has been defined as the ‘‘perceived vulnerability
or likelihood of harm if no action is taken and perceived severity or
seriousness of the consequences if harm was to occur” [7]. Concerns
about the risks of vaccination are known to be vaccine-specific
and have been shown to vary across countries and population
groups [8]. Responses to address these concerns should therefore
take into account a comprehensive understanding of perceived
vaccination risks as well as scientifically calculated ones. Previous
systematic reviews have studied determinants of vaccine hesi-
tancy, and reasons for refusing vaccinating, but few have focused
on risk perceptions in relation to the benefits of vaccination and
individual assessment of the risk-benefit balance. The aim of this
study is to review all available research published between 2004
and 2014 on vaccination risk perceptions across Europe.
This study is part of the ‘‘Accelerated development of vaccine
benefit-risk collaboration in Europe” (ADVANCE) project, which
aims to establish a system that rapidly provides best available sci-
entific evidence on vaccines benefits and risks.
2. Methods
The search strategy for the systematic literature review was
developed in the OVID Medline database by multiple reviewers
(Table 1). Keywords were selected in an effort to capture percep-
tions of risks, as well as confidence and/or hesitancy in vaccination.
The search aimed to identify studies published in English, French,
or Spanish from January 2004 to November 2014, from any of
the 28 countries of the European Union as well as Norway, Iceland,
Liechtenstein, and Switzerland. It was performed in November
2014, across OVID Medline, Embase, and Global Health, as well
as Scopus, Web of Science, and Open Grey.
Articles were imported into Endnote X7 (Thomson Reuters) to
remove duplicates, screen, and sort articles. Exclusion and inclu-
sion criteria were developed by multiple reviewers to facilitate
consistent screening of articles by titles and abstracts, done by a
single reviewer. Articles were included if they studied vaccine risk
perceptions or concerns, vaccine confidence and/or hesitancy, pub-
lic trust in vaccines, and general attitudes or beliefs about vaccina-
tion. There were no restrictions on study populations and types of
vaccines (apart from animal vaccines or vaccines not yet available).
The following were excluded: experimental studies, serologic
investigations, efficacy and safety trials, immunogenicity studies,
pre-clinical trials, cost-effectiveness or cost-benefit studies, edito-
rials, commentaries, conference abstracts, letters, and literature
or systematic reviews. Finally, articles focusing only on partici-
pants’ knowledge, reasons for getting vaccinated, socio-economic
determinants (i.e. age, level of income, education level), or inter-
ventions to increase vaccination coverage were excluded if they
did not include results about risks, perceptions, beliefs, hesitancy,
confidence, or trust in vaccines.
No meta-analysis was performed due to the substantial hetero-
geneity of studies. Data (study population, country, setting, vacci-
nes, year of publication, method, and concerns) was extracted
into a Microsoft Excel spreadsheet and a descriptive analysis of
concerns, beliefs and perceptions about vaccines was undertaken
instead. In order to combine and compare results across
quantitative and qualitative studies, the frequency of concerns
Table 1
Search strategy developed on Medline OVID.
1 ((vaccin$ or immunis$ or immuniz$) adj5 (anxiety or attitude$ or awareness or behavio?r or belief$ or criticis$ or doubt$ or distrust or dropout$ or exemption$ or
fear$ or hesitanc$ or trust or mistrust or perception$ or refus$5 or rejection or rumo?r$ or intent$5 or controvers$ or misconception$ or misinformation or
opposition or delay or dilemma$ or objector$ or resist$ or sceptic$)).ti,ab
2 ((vaccin$ or immunis$ or immuniz$) adj3 (uptake or barrier$ or choice$ or mandatory or compulsory or concern$ or accepta$ or knowledge or parent$ con$)).ti,ab
3 (((vaccin$ or immunis$ or immuniz$) adj5 confidence) not confidence interval).ti,ab
4 ((vaccin$ or immunis$ or immuniz$) adj5 decision making).ti,ab
5 ((vaccin$ or immunis$ or immuniz$) and (anti-vaccin$ or antivaccin$)).ti,ab
6 1 or 2 or 3 or 4 or 5
7 exp vaccination/ or Vaccines/ or Mass Vaccination/ or Immunization/ or exp Immunization Programmes/
8 Public Opinion/ or Attitude to Health/ or Attitude/ or Health Knowledge, Attitudes, Practice/ or ‘‘Patient acceptance of health care”/ or Treatment Refusal/ or
Parental Consent/ or Decision Making/ or Prejudice/ or Internet/
9 7 and 8
10 6 or 9
11 limit 10 to humans
12 europe/ or exp austria/ or exp belgium/ or exp estonia/ or exp latvia/ or exp lithuania/ or exp bulgaria/ or exp croatia/ or exp czech republic/ or exp hungary/ or exp
poland/ or exp romania/ or exp slovakia/ or exp slovenia/ or exp finland/ or exp france/ or exp germany/ or exp greece/ or exp iceland/ or exp ireland/ or exp italy/
or exp liechtenstein/ or exp luxembourg/ or exp cyprus/ or exp malta/ or exp portugal/ or exp denmark/ or exp norway/ or exp sweden/ or exp spain/ or exp
switzerland/ or exp great Britain/ or mediterranean region/ or mediterranean islands/ or netherlands/ or scandinavia/ or exp European Union/
13 11 and 12
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was calculated by adding the number of qualitative studies where
specific concerns were mentioned to the number of quantitative
studies where more than 20% of participants selected those con-
cerns. Although no theoretical framework was used to analyse
the results, the SAGE model of determinants of vaccine hesitancy
was used to guide the design of the search strategy, inclusion
and exclusion criteria, and data extraction and analysis [8].
3. Results
The search generated 2895 unique articles, from which 145
were selected for analysis (Fig. 1). Table 2 provides an overview
of articles included by country, population, and vaccine(s) studied.
The majority of articles included were from the United Kingdom
(35.2%), the Netherlands (11.7%), France (11.7%), Germany (8.3%),
Greece (7.6%), and Sweden (6.2%). They mostly studied vaccines
against seasonal influenza, human papillomavirus (HPV), pan-
demic influenza, measles-mumps-rubella (MMR) and childhood
VPDs in general. Finally, articles commonly studied healthcare
workers (HCWs), parents, adults, and individuals at high risk of
VPDs, including the elderly and patients with chronic illnesses
such as inflammatory bowel disease or systemic sclerosis.
Across all articles, the most common beliefs related to balancing
risks of vaccination to non-vaccination were about vaccine safety
(n = 107/145 articles) and the perceived low risk of contracting
VPDs (n = 51/145). Other important perceptions included beliefs
that VPDs are not dangerous (n = 36/145), vaccines do not work
(n = 32/145), vaccines are not needed (n = 24/145), adults or chil-
dren were healthy enough not to need vaccination (n = 20/145),
not enough evidence or adequate testing of vaccines (n = 21/145),
no recommendation to take the vaccine (n = 20/145) or a lack of
information about vaccines and/or VPDs (n = 31/145). All concerns
are listed in Fig. 2 and Figs. 3–5 provide an overview of the number
of studies with the five most important concerns by country,
population groups and vaccines. Concerns were analysed in more
depth for specific vaccines. Articles looking at different vaccines
without providing data on each vaccine separately [9–16] and
vaccines for which there were only a handful of articles available
[17–26] were excluded from the in depth analysis.
3.1. Seasonal influenza vaccines
The majority of studies (n = 50) investigated beliefs about the
seasonal influenza vaccine [27–76] and reported fears of adverse
Records idenﬁed through database searching  
(n = 7492) 
Records aer duplicates removed  
(n = 5020) 
Records screened  
(n = 2895) 
Full-text arcles assessed for eligibility  
(n = 284) 
Studies included in qualitave synthesis  
(n = 145) 
Records excluded  
(n = 2611) 
Full-text arcles excluded, with reasons  
(n = 139) 
Records excluded based on publicaon year 
(before 2004 or aer 2014)  
(n = 2125) 
Fig. 1. Selection of articles (PRISMA chart).
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reactions [27,29,33–37,41,43,45–49,57,59–63,71,73,74], and more
specifically, that vaccination causes influenza or flu-like symptoms
[34,35,44,71,74]. The second most common perception described
was that there was a low risk of contracting influenza [29,33,35,4
0,51,53,54,67,70,71,76] – many studies mentioned feelings of
strength and being healthy enough to fight influenza [34,35,39,
44,50,55,64,76], which was often described by study participants
as a mild illness [27,33,52,56–58,61,62,74,75]. Some studies also
reported feelings of protection linked to not having had flu in the
past [30,34,59,65], or because of regular exposure to the virus
[28,38]. Many studies reported that participants also believed they
did not qualify for the vaccine as they were not part of a high risk
group [28,37,38,44,51,52,54,55,61,64,71,72,76], while others
explained they had not been offered the vaccine [27,51,52,54,61,
63,66,68,69,71,74]. On the other hand, other studies reported
beliefs that seasonal influenza vaccination is not effective in pre-
venting infection [50,60,63,67], that vaccination is not a priority [
30,34,44,47,47,52,54,64,66,71], or not necessary [31,35,42,43,
65,69].
General mistrust was reported around influenza vaccination,
with some studies showing individuals refusing all vaccines
[37,56,67,69,72], and others describing conspiracy theories [75]
and mistrust of health authorities [49,75], of the seasonal influenza
vaccines [69,75], or of pharmaceutical companies [75]. Some stud-
ies reported a perceived lack of information [35,75], misunder-
standings [48,74], beliefs that the vaccine is developed too
quickly every year [49], and negative information about vaccine
safety in the media [69,71]. Perceptions were reported to be influ-
enced by a negative previous experience with the vaccine [34,68],
and advice from others against vaccination [62,68]. Finally, some
studies discussed the balance (or imbalance) of risk perceptions
over perceived benefits of vaccination [61,74], fear of injections
[34], adjuvants [73], and/or a preference for homeopathy [37].
3.2. Pandemic influenza vaccines
Out of 34 articles on pandemic influenza vaccination, one stud-
ied the H5N1 [77] and 33 the AH1N1 [27–32,65,72,78–103] pan-
demic influenza vaccines. The most frequent concern cited across
studies was the opinion that these vaccines could have dangerous
adverse reactions [27–31,77–79,81–90,92,94–103]. This was often
explained by study participants as a perception that these new vac-
cines were developed too quickly [80,100], resulting in insufficient
testing and evidence [31,80,85,86,93,94,98,100,102] and informa-
tion about long term adverse reactions [82,83,93,95,96]. Studies
reported that concerns about inadequate testing also resulted in
perceptions of low vaccine effectiveness [32,79,81,86,89,96,98].
The second most important reason for hesitating to vaccinate
was the belief that pandemic influenza is not a threatening illness
and is comparable to a mild flu [27,72,78,80,81,86,89,96,98,99,10
1–103]. Many studies also discussed a perceived low risk of con-
tracting pandemic influenza [31,65,77,84,86,88,89,91,94,97,101]
because of protection from a strong immune system [27,31,86]
or previous exposure to the virus [28]. Some studies mentioned
that healthcare workers were not part of at risk groups or they
did not come into contact with patients [28,72,80].
Other studies discussed participants being influenced by nega-
tive media reports [82,86] and contradictory messages [98] about
vaccines; while some believed the media overstated the serious-
ness of AH1N1 [103]. Mistrust was reported towards vaccines
[100,103], national and international health authorities [86], and
pharmaceutical companies [86]. Other studies reported a prefer-
ence for natural prevention methods [78,86,97,100], a lack of
health care provider recommendation [97], previous negative
experiences with vaccination [27], the belief that the vaccine could
cause flu [78], doubts about the risk-benefit balance [93], the belief
that infection strengthens the immune system and that individuals
should be brave and face diseases [86], notions of fatalism [86], and
fear of injections [86].
3.3. HPV vaccines
In the 29 articles that studied HPV vaccination [104–132], the
most common concerns identified were about safety, and particu-
larly unknown adverse reactions that might develop long after vac-
cination [104–110,112,113,115–120,123–127,129–132]. These
concerns often came with discussion around the newness of the
vaccine [104,107,112,113,117,126,129], and claims that it has not
been tested long enough [104,105,107,115,122,129–131]. Many
articles reported concerns about a lack of clear information around
HPV infection and vaccination, and individuals feeling that they
have insufficient knowledge to make an informed decision [104,1
08,109,112,116,118–121,127,128,132]. Some also mentioned that
participants believed insufficient testing of the vaccine meant
there were too many uncertainties around long-term effectiveness
of the vaccine [107,109,112,113,119,131].
Table 2
Characteristics of included studies.
Countries Studied populations Vaccines Study method
Country # Population # Vaccine # Method #
United Kingdom 51 HCWs 37 Seasonal influenza 50 Structured questionnaires
(mailed, online, telephone or face to face)
98
The Netherlands 17 Parents 30 Pandemic influenza 34 Qualitative interviews 23
France 17 Adults 17 HPV 29 Focus groups 10
Germany 12 High risk groups 17 MMR 12 Focus groups and qualitative interviews 6
Multiple countries 13 Multiple populations 10 Childhood 11 Mixed methods: qualitative interviews/focus
groups and structured questionnaires
5
Greece 11 Medical students 7 Hepatitis B 2 Web monitoring 2
Sweden 9 Young women 5 Anthrax 2 National statistics 1
Spain 3 Children & teenagers 6 Varicella 1
Italy 3 Pregnant women 5 DTaP/IPV/Hib 1
Romania 2 Religious communities 3 Pertussis 1
Denmark 1 Anthroposophical communities 2 Pneumococcal 1
Austria 1 Internet users 2 All vaccines in general 1
Hungary 1 Armed forces 2
Ireland 1 Households 2
Poland 1
Slovenia 1
Switzerland 1
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Some studies reported beliefs that children are too young to
receive the HPV vaccine [104,107,118,119,121,122,126], and fears
of a ‘‘sexually transmitted infection vaccine” leading to unsafe
sexual behaviours and increased promiscuity [107,110,117,121,
124,125,130]. Some also discussed personal values or faith issues
[104,110,122], and others the difficulty of talking about a ‘‘sex vac-
cine” [110,112,117,132]. Another important belief was that there is
no risk of contracting HPV [112,114,122,129,130] and therefore no
need for vaccination [105,112,115,122,130]. The perception that
the risks of vaccination are higher than benefits were more
common than for other vaccines [106,107,118,130] and one study
mentioned the perception that HPV infection is not a serious illness
[129].
Mistrust was common, especially of pharmaceutical companies
[105,106,118,130], government [104,109,123], research [112,130],
and health authorities [118,130]. Two studies reported conspiracy
theories about vaccines causing sterilisation [118,130] and others
expressed concerns about the vaccine not being natural
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Fig. 2. Most common concerns about risks and benefits of vaccination in Europe.
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[104,130], and a preference for homeopathy, screening or sexual
abstinence [105,117,130]. There were also beliefs that HPV infec-
tion can strengthen the immune system [104].
Issues about vaccine providers were raised in some studies,
such as a lack of patient trust in their doctors [130], the fact that
some doctors do not recommend the HPV vaccine [117,130], doc-
tors being dismissive of parents’ concerns [104,123], or doctors
pressuring to vaccinate [104]. Some studies reported that parents
discussed parental responsibility to protect children against vac-
cine adverse reactions [104,105,107], and others the influence of
negative media reports [104,129].
Finally, there were also reports of general anti-vaccination feel-
ings [104,130], beliefs that children receive too many vaccines
[123,124], that their immune systems are too fragile [104,107], a
lack of privacy when being vaccinated [111,132], concerns about
pain of injection and cleanliness of needles [111,116], and the
importance of parental consent for vaccination [115,130].
3.4. MMR vaccines
Twelve articles studied MMR vaccination [132–142] and found
that the most important concerns were about safety, with some
articles reporting particular worries about autism [132,134,136–1
38,140,141]. A few studies also reported beliefs that the diseases
prevented by the MMR vaccine are mild, treatable, and not danger-
ous [135,138,140,142] and that children actually benefit from
these infections [134,141,142]. Mistrust of governments was high
[135,137,139], together with perceptions that doctors are dismis-
sive of parents safety concerns [133,137,142]. Lack of trust was
reported towards health authorities [132], pharmaceutical compa-
nies [139], researchers [135], and doctors [142].
Some information challenges were reported, including a lack of
information [139,140], perceptions about inadequate evidence of
vaccine safety [137,139], and reports of conflicting messages
[133,135]. Some studies found that participants felt that children
are too fragile [133] to receive vaccines with too many antigens
[134], and therefore preferred homeopathy [134,136]. Two studies
reported influences from negative previous experiences with MMR
vaccination [139,142] and another two studies found participants
believed healthy children do not need the vaccine [134,138]. One
study found that parents believe the risks of vaccinating are higher
than benefits [142]. Other parents were reported to believe that
children are too young to be vaccinated [136] and to express con-
cerns about adjuvants as well as the fear vaccination could create
new disease strains [138]. Finally, studies found that parents of
autistic children blamed themselves for vaccinating their children
[133].
3.5. Childhood vaccination
Eleven articles studied concerns about childhood vaccination in
general [143–154]. The most common concerns were about
adverse reactions [144–148,150–154]. Other studies reported that
participants believed that vaccine preventable diseases are not
dangerous [147,148,150] but instead are beneficial for child devel-
opment [149,150]. Some also believed that risks of vaccination out-
weigh benefits [147,150,154]. Studies found that interviewed
participants reported inadequate information and evidence
[143,144,147,153] and disagreements between experts on vaccine
safety [144].There were beliefs that vaccines do not work or have a
short duration of protection [143,146,150,154], supporting the per-
ception that vaccines are not useful [146,153,154].
Lack of trust in health authorities [147,154] and doctors [147]
was reported, with patient reports of doctors only discussing the
benefits of vaccination [145]. Studies found that parents reported
being influenced by friends and families [150], negative reports
in the media [150,153], previous negative personal experience
[150], and society [152]. Other concerns mentioned in studies were
about combination vaccines [147], adjuvants [150], children
receiving too many vaccines [145], and injecting foreign sub-
stances into the body [152].
Studies found that parents from religious communities reported
strong trust in God, and beliefs that they should not interfere with
divine providence [151,152], as well as the perception that separa-
tion from other communities lowers the risk of infectious diseases
transmission [152]. Some studies also reported that parents who
visit anthroposophical child welfare centres explained that healthy
children do not require vaccination [149], and that alternative pre-
vention methods should be favoured as the immune system is not
developed enough to handle vaccines [150].
4. Discussion
Over the past decade, a number of studies have been pub-
lished that help to characterise risk perceptions relating to vacci-
nes and vaccination by European populations, and their findings
have been reviewed, analysed and summarised in this article.
The majority of studies were conducted in the United Kingdom,
France and the Netherlands, with a main focus on the seasonal
influenza vaccine, the HPV vaccine and the pandemic influenza
vaccine. These characteristics could be a reflection of the presence
of research institutes in these countries with relevant research
interests but could also be linked to the introduction of and the
high number of safety concerns about the HPV vaccine, the poor
uptake of H1N1 vaccination during the 2009 pandemic, as well as
previous historic vaccination crisis in these countries such as the
MMR-autism crisis in the UK [144,155] or the hepatitis B-
multiple sclerosis crisis in France [156]. As no country is safe
from a potential decrease of public confidence in vaccination,
more robust behavioural research needs to be conducted particu-
larly in countries where fewer studies were identified, such as
Eastern Europe. This review also points to the need for the use
of media monitoring tools that listen to populations’ concerns
in ‘‘real-time” given the changing nature of sentiments. While
surveys, questionnaires and qualitative research are useful for
exploring public concerns about vaccination, they fail to detect
sudden changes in confidence levels. For instance, although this
study reviewed articles published between 2004 and 2014, it
failed to detect concerns raised in Denmark about HPV vaccina-
tion that started in 2013. There are currently very few such sys-
tems in place [157], but as European citizens are increasingly
exposed to health information on the internet and social media
[158], it is important to continuously monitor and analyse online
information to detect any changes in perceptions of vaccinations
risks.
Across all countries and vaccines, the largest area of concern
was vaccine safety. Different types of concerns about vaccine
safety were however identified for different vaccines: for instance,
while perceived adverse events described for HPV vaccination
were often long-term and severe, those for influenza vaccination
were milder and often consisted of the beliefs that the vaccine
causes flu-like symptoms. There were also reports of more general
fears observed for all vaccines, related to uncertainty about the
safety of the vaccine. Uncertainty issues reveal a different chal-
lenge: the one of mistrust, for instance of information provided
about the safety of the vaccine. While providing comprehensive
and up-to-date information to the public about the risks and the
benefits of vaccination is essential, these findings show that they
need to be complemented by trust building strategies to sustain
vaccine coverage and acceptance. Population perceptions of risk
might also reveal real safety issues; and it is therefore important
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not to dismiss those concerns, but instead to consider them care-
fully and to investigate them further where appropriate.
Other major concerns identified included perceptions of low
likelihood of contracting VPDs and perceived low severity of dis-
eases. These results can partially be explained by the high number
of new vaccine products which have been introduced in Europe
over the past decade, as well as the decrease in prevalence of VPDs
for older and routine vaccines [7,156,159,160]. Vaccination is often
thought to be a victim of its own success [1,161]: as VPDs are elim-
inated from regions with high vaccination coverage and adverse
VPDs outcomes become less visible, individuals have no first-
hand knowledge of the risks of these diseases and start questioning
the benefits of vaccination over the risks [7]. The review also found
that although some concerns are important for all vaccines (i.e.
perceived adverse events, or mistrust), some are more common
in relation to specific vaccines. For instance, concerns about flu
vaccination are typically related to not perceiving a need for the
vaccine or not believing the disease is severe, while concerns about
new vaccines such as H1N1 or HPV are linked to uncertainties and
the belief there is insufficient evidence or testing of the vaccine.
Reports of individuals believing that risks outweigh the benefits
of vaccination were reported for all vaccines. This is problematic,
as individual decision-making has been shown to be more affected
by perceived losses rather than equivalent gains [162–165]. If indi-
viduals make decisions about vaccination based on how they per-
ceive different risks, it is important that they understand the risks
of not vaccinating in terms of susceptibility to and severity of VPDs.
While scientists tend to talk about risks for populations and public
health (i.e. rate of VPDs in a population), individuals are mostly
interested in individual risks for themselves and their children
(i.e. individual side effects), which should be considered when
designing communication strategies. This could be reflected in vac-
cine provider communication to parents, which should acknowl-
edge parental individual risk perceptions and present both risks
and benefits of vaccination at an individual rather than a popula-
tion level. Official information documents about vaccination
should also be developed to focus both on individual and popula-
tion risks and benefits of vaccination.
Another important issue reported in this review is the public
perception that there is a lack of adequate information about all
vaccines. Although this is partly linked to quality of the communi-
cation and information system, it is also largely influenced by mis-
trust. This is reflected by the fact that some studies found that
participants were still describing concerns that MMR might cause
autism although they knew that experts and scientists had not
found any evidence for this association. Providing information is
not, by itself, sufficient to change people’s behaviour. Some studies
show that vaccine refusers are usually more informed than vaccine
acceptors, as they often research information themselves online or
talk to other parents about their experiences with vaccination
[7,157,166]. It is therefore important to move beyond ‘‘knowledge
deficit models of communication” and develop tailored
communication and engagement strategies with an effective lis-
tening mechanism, that provide for continuous listening to popula-
tions’ perceptions of vaccines. A proactive approach to responding
to vaccination scares should be encouraged with communication
strategies ready in advance to respond to different types of
challenges and concerns [158]. Certain tools, such as the WHO
guidance on ‘‘How to respond to vocal vaccine deniers in public”
[167], are available to help national immunisation programme
managers prepare such strategies. Managing inaccurate percep-
tions of vaccinations risks is as important as the management of
scientifically confirmed risks [157]. Communication strategies
should be developed as a dynamic process and include input from
a range of actors such as immunisation managers, vaccine provi-
ders, but also parents [7,158].
4.1. Limitations
There are some limitations to this review which should be con-
sidered when interpreting results. The selection of articles and data
extraction of the systematic review was conducted by one
researcher and quality assessment of the articles was not per-
formed. The impact of this limitation was attenuated by using mul-
tiple researchers to develop the search strategy and the exclusion
and inclusion criteria, and closely review the data extraction and
analysis. Only articles published in English, French and Spanish
were included in the analysis which might have led to under-
representation of certain countries. Two separate analysis for qual-
itative and quantitative studies identified by the review might
have provided more detailed results, while the arbitrary decision
to select concerns reported by a minimum of 20% of study partic-
ipants might have impacted the results. Finally, articles published
after November 2014 were not included in this review; the authors
suggest updating the review regularly to detect any changes in
concerns about the risks and benefits of vaccination in Europe.
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